| A dominant mutation in human RAD51 reveals its function in DNA interstrand crosslink repair independent of homologous recombination AT Wang, T Kim, JE Wagner, BA Conti, FP Lach, AL Huang, H Molina, ... Molecular cell 59 (3), 478-490, 2015 | 293 | 2015 |
| XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair N Bhagwat, AL Olsen, AT Wang, K Hanada, P Stuckert, R Kanaar, ... Molecular and cellular biology 29 (24), 6427-6437, 2009 | 171 | 2009 |
| SnapShot: Fanconi anemia and associated proteins AT Wang, A Smogorzewska Cell 160 (1), 354-354. e1, 2015 | 170 | 2015 |
| Human SNM1A and XPF–ERCC1 collaborate to initiate DNA interstrand cross-link repair AT Wang, B Sengerová, E Cattell, T Inagawa, JM Hartley, K Kiakos, ... Genes & development 25 (17), 1859-1870, 2011 | 168 | 2011 |
| Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH: cytochrome P450 oxidoreductase under hypoxia CP Guise, AT Wang, A Theil, DJ Bridewell, WR Wilson, AV Patterson Biochemical pharmacology 74 (6), 810-820, 2007 | 101 | 2007 |
| BRD4 facilitates replication stress-induced DNA damage response J Zhang, AM Dulak, MM Hattersley, BS Willis, J Nikkilä, A Wang, A Lau, ... Oncogene 37 (28), 3763-3777, 2018 | 85 | 2018 |
| Orchestrating the nucleases involved in DNA interstrand cross-link (ICL) repair B Sengerová, AT Wang, PJ McHugh Cell cycle 10 (23), 3999-4008, 2011 | 66 | 2011 |
| Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue-and CB1-receptor-specific mechanism MD Mitchell, TA Sato, A Wang, JA Keelan, AP Ponnampalam, M Glass American Journal of Physiology-Endocrinology and Metabolism 294 (2), E352-E356, 2008 | 65 | 2008 |
| Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand cross-links KA Rickman, RJ Noonan, FP Lach, S Sridhar, AT Wang, A Abhyankar, ... Genes & development 34 (11-12), 832-846, 2020 | 54 | 2020 |
| SLFN11 informs on standard of care and novel treatments in a wide range of cancer models C Winkler, J Armenia, GN Jones, L Tobalina, MJ Sale, T Petreus, T Baird, ... British Journal of Cancer 124 (5), 951-962, 2021 | 46 | 2021 |
| Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance V Serra, AT Wang, M Castroviejo-Bermejo, UM Polanska, M Palafox, ... Clinical Cancer Research 28 (20), 4536-4550, 2022 | 19 | 2022 |
| Identifying and overcoming a mechanism of resistance to WEE1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells MK Gomez, JP Thomson, GR Grimes, AT Wang, M Churchman, ... European Journal of Gynaecological Oncology 43 (2), 183-95, 2022 | 6 | 2022 |
| Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models MJ O'Connor, R Odedra, S Palakurthi, A Hughes, Z Lai, P Kirschmeier, ... European Journal of Cancer 1 (69), S142, 2016 | 4 | 2016 |
| Biomarkers for inhibitors of the replication stress response proteins WEE1 and ATR in triple negative breast cancer V Serra, C Cruz, Z Lai, M Castroviejo-Bermejo, M Palafox, UM Polanska, ... Cancer Research 79 (13_Supplement), 3503-3503, 2019 | 2 | 2019 |
| Reversing PARP inhibitor resistance by targeting the replication stress response MJ O'Connor, C Cruz, M Castroviejo-Bermejo, UM Polanska, GN Jones, ... Cancer Research 79 (13_Supplement), 932-932, 2019 | 1 | 2019 |
| Apollo: a healer of the genome? AT Wang, PJ McHugh Cell Cycle 8 (13), 1979-1983, 2009 | 1 | 2009 |
| Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance V Serra Elizalde, AT Wang, M Castroviejo Bermejo, UM Polanska, ... American Association for Cancer Research, 2022 | | 2022 |
| CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, combined with DDR agents provides a novel approach to increasing therapeutic index LO O'Connor, AT Wang, D Jones, R Odedra, M Spreadborough, J Wilson, ... MOLECULAR CANCER RESEARCH 15, 2017 | | 2017 |
| Abstract B32: CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, combined with DDR agents provides a novel approach to increasing therapeutic index LO O'Connor, AT Wang, D Jones, R Odedra, M Spreadborough, J Wilson, ... Molecular Cancer Research 15 (4_Supplement), B32-B32, 2017 | | 2017 |
| A camptothecin-containing nanoparticle-drug conjugate combination with DDR agents provides a novel approach to increasing therapeutic index L Oplustil O’Connor, AT Wang, DR Jones, R Odedra, M Spreadborough, ... Cancer Research 76 (14_Supplement), 3721-3721, 2016 | | 2016 |
